Cited by 1,008T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Open access

Sutmuller, Roger P.M., van Duivenvoorde, Leonie M., van Elsas, Andrea, Schumacher, Ton N.M., Wildenberg, Manon E., Allison, James P., Toes, Rene E.M., Offringa, Rienk, Melief, Cornelis J.M.·2001·The Journal of Experimental Medicine

DOI 10.1084/jem.194.6.823PMC PMC2195955

Open this paper in CoChat — free account

Abstract

Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the CD25+ regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25+ Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-related protein 2180–188–specific CTLs detected in the periphery. Furthermore, tumor rejection is dependent on the CD8+ T cell subset. Our data demonstrate that the CTL response against melanoma antigens is an important component of the therapeutic antitumor response and that the reactivity of these CTLs can be augmented through interference with immunoregulatory mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25+ Treg cells indicates that CD25+ Treg cells and CTLA-4 signaling represent two alternative pathways for suppression of autoreactive T cell immunity. Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.194.6.823

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“H-2K b tetramers were produced as described previously (20, 21) and stored frozen in Tris-buffered saline/16% glycerol/0.”
Method
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Anderson Cancer Center, Houston, TX), GM-CSF‐producing B16 cell lines BL6/GM-E, BL6/GM18 (18), B16/B7.1 (18), 9H10 ( 19 ), and PC61 (American Type Culture Collection) were cultured in Iscove’s IMDM (BioWhittaker) supplemented with 1 U/ml penicillin, 1 � g/ml streptomycin, 2 � M L -glutamine, 20 � M � -mercaptoethanol…”
MethodSelf-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,566

Flagged first, then by citations

Show all 44 references

3 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 801–900 of 1,000

Chimeric acceleration by donor CD4+CD25+T-reg depleted fraction in splenocyte transplantation
Kutsuna, N., Yamazaki, S., Kaiga, T., Inagaki, Y., Hayashi, Y., Kanamoto, A., Okada, S., & Takayama, T. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.01.003 · Cited by 6
Immunotherapy and Cancer Therapeutics: Why Partner?
Emens, L. A., & Jaffee, E. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50076-6 · Cited by 6
Prospects for the use of ipilimumab in treating advanced prostate cancer
Wei, X. X., Fong, L. H., & Small, E. J. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1136284 · Cited by 5
Mechanisms of Central and Peripheral T-Cell Tolerance: An Update
Buer, J., Westendorf, A. M., Zeng, A., HeFeng, F. Q., Hansen, W., & Probst‐Kepper, M. (2005) · Transfusion Medicine and Hemotherapy · doi:10.1159/000089128 · Cited by 5
Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer
Jorritsma, A., Bins, A. D., Schumacher, T. N., & Haanen, J. B. A. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5254 · Cited by 5
Self-citation
Variations in the number of regulatory T cells (CD4+CD25+) in patients with breast cancer during Herceptin therapy
Григорьевна, С. Е., Ивановна, Ч. А., Заботина, Т. Н., Петровна, Г. И., & Lichinitser, M. (2006) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-006-0171-7 · Cited by 5
The role of regulatory T cells in the modulation of anti-tumor immune response
Radosavljevic, G. D., Jovanović, I., Kanjevac, T., & Arsenijević, N. (2013) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1304262r · Cited by 5
Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors
Zhang, C., Chien, C., Jurgaitytė, E., Sakiyama, K., Bockman, A., Jo, Y., Lee, S., Silveria, S. L., Andrews, E., Mende, A., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adx4411 · Cited by 4
Novel Agents to Improve Outcome of Allogeneic Transplantation for Patients with Multiple Myeloma
Kortüm, K. M., Knop, S. T., & Einsele, H. (2010) · Future Oncology · doi:10.2217/fon.10.162 · Cited by 4
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Self-citation
The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression
Dey, M., Chang, A. L., Miska, J. M., Qiao, J., & Lesniak, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00003-x · Cited by 4
Microenvironment and Lung Cancer
Walser, T. C., Liclican, E. L., O'Byrne, K. J., Cho, W. C. S., & Dubinett, S. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00014-7 · Cited by 4
Pathways of Dysregulation in Renal Cell Carcinoma: Rational Approaches to Development of Novel Treatment
Khasawneh, M. K., & Bukowski, R. M. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.s.002 · Cited by 4
Current immunotherapy of melanoma
Riker, A. I., Sondak, V. K., Fishman, M., DAUD, A. I., & Pilon‐Thomas, S. (2005) · Clinical and Applied Immunology Reviews · doi:10.1016/j.cair.2005.01.002 · Cited by 4
Novel Immunotherapy to Eliminate Minimal Residual Disease in AML Patients
Liu, H. (2013) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000112 · Cited by 4
The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics
Salas, R. N., Finke, J. H., & Rini, B. I. (2007) · Targeted Oncology · doi:10.1007/s11523-007-0064-3 · Cited by 4
El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones virales crónicas
Alfaro, C., Murillo, O., Tirapu, I., Azpilicueta, A., Huarte, E., Arina, A., Arribillaga, L., Perez‐Gracia, J. L., Bendandi, M., Prìeto, J., et al. (2006) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272006000100007 · Cited by 4
Failure of Vaccination With Idiotypic Protein or DNA, (+/???IL-2), the Depletion of Regulatory T Cells, or the Blockade of CTLA-4 to Prolong Dormancy in Mice With BCL1 Lymphoma
Pop, L. M., Smallshaw, J. E., Tucker, T. F., Stevenson, F. K., & Vitetta, E. S. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175493.05852.5a · Cited by 4
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop
Houot, R., Gaulard, P., Schreiber, R. D., Mellman, I., Lambotte, O., Coulie, P. G., Fest, T., Korman, A. J., Levy, R., Shipp, M. A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1186323 · Cited by 4
Virus‐based immunotherapy of cancer: what do we know and where are we going?
Sørensen, M. R., & Thomsen, A. R. (2007) · Apmis · doi:10.1111/j.1600-0643.2007.00802.x · Cited by 4
Autoimmune Gastritis Is a Well-Defined Autoimmune Disease Model for the Study of CD4+CD25+ T Cell-Mediated Suppression
McHugh, R. S. (2005) · Springer eBooks · doi:10.1007/3-540-27702-1_8 · Cited by 4
Increasing Therapeutic Gain and Controlling Radiation-Induced Injuries with Asian Botanicals and Acupuncture
Sagar, S. M., & Wong, R. K. W. (2009) · Springer eBooks · doi:10.1007/978-90-481-3555-4_6 · Cited by 4
Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein
Mincheff, M. S., Zoubak, S., Altankova, I., Tchakarov, S., Васильович, П. П., Em, M., Botev, C., & Meryman, H. T. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700778 · Cited by 4
Boosting the immune response: an alternative combination therapy for cancer patients.
Thyphronitis, G., & Koutsilieris, M. (2004) · PubMed · Cited by 4
CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo
Tilsed, C. M., Fong, K. P., Shi, X., Akimova, T., Wang, L., Noguera-Ortega, E., Krouse, R., Bermudez, A. F., Singhal, S. K., Young, R. M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017573 · Cited by 3
Safety assessment of immunomodulatory biologics: The promise and challenges of regulatory T-cell modulation
Ponce, R. A. (2011) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.603390 · Cited by 3
The Effects of Immunosuppression on Regulatory CD4+CD25+ T Cells
Javeed, A., & Zhao, Y. X. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256281 · Cited by 3
Immunopathogenesis of Acute Pancreatitis
Булава, Г. В. (2022) · Russian Sklifosovsky Journal Emergency Medical Care · doi:10.23934/2223-9022-2022-11-3-484-492 · Cited by 3
RA8, A Human Anti-CD25 Antibody Against Human Treg Cells
Arias, R. S., Flanagan, M. L., Miller, K. D., Nien, Y.-C., Hu, P., Gray, D., Khawli, L. A., & Epstein, A. L. (2007) · Hybridoma · doi:10.1089/hyb.2006.0041 · Cited by 3
Innate and Adaptive Immune Responses to Cancer
Hastings, K. T., & Rausch, M. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-38983-2_4 · Cited by 3
Immunoglobulin light chain, Blimp‐1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis
Flies, A., Ahmadi, T., Parks, A. J., Prokaeva, T. B., Weng, L., Rolfe, S. S., Seldin, D. C., & Sherr, D. H. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.73 · Cited by 3
Scientific contributions toward successful cancer immunotherapy in The Netherlands
Melief, C. J. M., Scheper, R. J., & de Vries, I. J. M. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.10.012 · Cited by 3
Self-citation
Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody
Kontani, K., Teramoto, K., Ozaki, Y., Sawai, S., Tezuka, N., Ishida, H., Kajino, K., Fujino, S., Yamauchi, A., Taguchi, O., et al. (2007) · Oncology Reports · doi:10.3892/or.17.4.895 · Cited by 3
Taming regulatory T cells by autologous T cell immunization: A potential new strategy for cancer immune therapy
Zhang, Y., Wang, L., Li, D., & Li, N. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.01.026 · Cited by 3
Correlation between CD4+CD25+Treg cells and CCR4 in nasopharyngeal carcinoma
Ren, Y., Sui, J., Song, X., Wong, G. W., Ma, J., Yao, H., Lin, M. C. M., & Li, X. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0567-7 · Cited by 3
Cancer Immunology
Pardoll, D. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00006-0 · Cited by 4
The role of regulatory T cells in cutaneous disorders
Birch, K. E., Vukmanovic‐Stejic, M., Reed, J. R., Rustin, M. H. A., & Akbarl, A. N. (2005) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7301-6_11 · Cited by 3
Interactions at the Dendritic Cell / T-Cell Interface Define the Balance between Immunity and Tolerance
Iruretagoyena, M., Lezana, J. P., & Kalergis, A. M. (2005) · Transfusion Medicine and Hemotherapy · doi:10.1159/000089127 · Cited by 3
Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies
Kami, M. (2004) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyh139 · Cited by 3
Lung Cancer and Immune Dysfunction
Dubinett, S. M., Sharma, S. P., Huang, M., Mao, J. T., & Batra, R. K. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-743-7_18 · Cited by 3
Future directions for vaccine-based therapies
Vieweg, J. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.08.012 · Cited by 3
Manipulating T regulatory cells in cancer immunotherapy
Rüter, J., Barnett, B. G., Kryczek, I., Brumlik, M. J., Daniel, B. J., Coukos, G., Zou, W., & Curiel, T. J. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.4.589 · Cited by 3
Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses
Hargadon, K. M. (2013) · Journal of Cosmetics Dermatological Sciences and Applications · doi:10.4236/jcdsa.2013.32a002 · Cited by 2
TGF-Beta and Regulatory T Cells
Wan, Y. Y., & Flavell, R. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-77909-6_6 · Cited by 2
Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies
Khansari, N. (2015) · MOJ Immunology · doi:10.15406/moji.2015.02.00062 · Cited by 2
Cancer Immunotherapy with Vaccines and Checkpoint Blockade
Pardoll, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00052-4 · Cited by 2
Improved generation of anti-tumor immunity by antigen dose limitation
Shofner, J., Vasquez, J. G., Berger, C. L., & Edelson, R. L. (2007) · Journal of Immune Based Therapies and Vaccines · doi:10.1186/1476-8518-5-2 · Cited by 2
Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Hoffmann, P., Eder, R., Kunz‐Schughart, L. A., Andreesen, R., & Edinger, M. (2004) · Cancer Cell International · doi:10.1186/1475-2867-4-s1-s11 · Cited by 2
Update on T‐cell immunity: Implications for tumor immunology
McCluskey, J. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01381.x · Cited by 2
Frontiers in Cancer Immunotherapy
Murphy, J. F. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_1 · Cited by 2
Immunotherapy for Renal Cell Carcinoma
Davar, D., Fenton, M. J., & Appleman, L. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-062-5_16 · Cited by 2
Vaccine Therapy and Immunotherapy for Pancreatic Cancer
Zheng, L., & Jaffee, E. M. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_53 · Cited by 2
Activation of Vα24NKT cells in malignant pleural effusion in patients with lung cancer
Shimizu (2009) · Oncology Reports · doi:10.3892/or_00000475 · Cited by 2
Recent advances in the use of antigen-specific T cells for the treatment of cancer
Yee, C., Wallen, H. D., Hunder, N. N. H., Thompson, J. A., Byrd, D. R., Reilly, J. Z., Hendricks, D. W., Kenyon, K., & Schirmer, L. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.06.002 · Cited by 2
Is immunotherapy a reasonable approach for the treatment of esophageal cancer?
Friedl, J., Riss, S., & Stift, A. (2007) · European surgery. Supplement/European surgery · doi:10.1007/s10353-007-0334-4 · Cited by 2
Initiating protective T cell immunity by targeting antigens directly to maturing dendritic cells in lymphoid tissues
Steinman, R. M., Trumpfheller, C., Liu, K., Bonifaz, L. C., Finke, J., Granelli‐Piperno, A., & Nussenzweig, M. C. (2005) · International Congress Series · doi:10.1016/j.ics.2005.07.095 · Cited by 1
Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer
Chmielowski, B., & Ribas, A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_48 · Cited by 1
Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581
Banham, A. H., & Pulford, K. A. F. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902785183 · Cited by 1
Immunotherapy of skin diseases by targeting T cells
Bachelez, H. (2003) · Experimental Dermatology · doi:10.1111/j.0906-6705.2003.0156i.x · Cited by 1
Immunopathology and Immunotherapy of Myeloid Leukemia
Snauwaert, S., Vandekerckhove, B., & Kerre, T. C. C. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_5 · Cited by 1
Regulatory T Cells and Cancer
Turk, M. J. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_1 · Cited by 1
Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer
Berzofsky, J. A., Wood, L. V., & Terabe, M. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-21167-1_2 · Cited by 1
Cancer-Specific Vaccines
Pardoll, D. M. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10054-8 · Cited by 1
Development of novel immune interventions for genito-urinary cancers
Agarwal, N., & Vogelzang, N. J. (2013) · CRC Press eBooks · doi:10.3109/9781841848303-4 · Cited by 1
Regulatory T cells in Tumor Immunity: Role of Toll-Like Receptors
Wang, R. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50079-1 · Cited by 1
A Peptide-Based Platform for Displaying Antibodies to Engage T Cells
Zheng, Y. (2010) · Cited by 1
Immunologie et cancer: m�canismes d?�chappement tumoraux
Calmels, B. (2004) · ONCOLOGIE · doi:10.1007/s10269-005-0124-1 · Cited by 3
Cancer Immunology
Pardoll, D. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50009-9 · Cited by 1
Vaccination to treat noninfectious diseases: surveying the opportunities
Martin, S. W., & Bachmann, M. F. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50018-6 · Cited by 1
Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma
Qian, X., Kaufmann, A. M., & Albers, A. E. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_15 · Cited by 1
IL-28 and IL-29 in Regulation of Antitumor Immune Response and Induction of Tumor Regression
Numasaki, M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0170-5_5 · Cited by 1
Chapter 21 – Vaccination to Treat Noninfectious Diseases: Surveying the Opportunities
Bachmann, M. F., & Vogel, M. (2006) · Academic Press eBooks · Cited by 1
Lung Tumor Microenvironment and Myelomonocytic Cells
Srivastava, M. K., Andersson, Å., Zhu, L., Harris‐White, M. E., Jay, M., Dubinett, S. M., & Sharm, S. (2012) · InTech eBooks · doi:10.5772/33119 · Cited by 1
Clinicopathological Significance of FOXP3 Expression in EsophagealSquamous Cell Carcinoma
Wada, Y., Date, Y., Ohike, N., Tsukuda, G., Asonuma, K., Morohoshi, T., Motegi, K., Yamashita, T., Ariyoshi, T., Goto, S., et al. (2013) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.25.133 · Cited by 1
Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines)
Liu, X., & Kline, J. P. (2015) · Springer eBooks · doi:10.1007/978-4-431-55726-5_4 · Cited by 1
Regulatory T Cells
Thornton, A. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00605-9 · Cited by 1
Immunotherapy using Regulatory T Cells in Cancer Suggests More Flavors of Hypersensitivity Type IV
Pakravan, N., & Hassan, Z. M. (2018) · Immunotherapy · doi:10.2217/imt-2017-0129 · Cited by 1
The Role of Regulatory T Lymphocytes in Immune Control of MC-2 Fibrosarcoma
Jukić, T. (2020) · Acta Clinica Croatica · doi:10.20471/acc.2020.59.02.20 · Cited by 1
Cancer Immunology
Tseng, D., Schultz, L. M., Pardoll, D. M., & Mackall, C. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00006-2 · Cited by 2
Immunotherapy for Human Cancer
Cardoso, A. A., Haining, W. N., Leite, M., & Maia, S. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-664-5_16 · Cited by 1
Regulatory T. Cells
Fehervari, Z. T., & Sakaguchi, S. (2005) · Elsevier eBooks · doi:10.1016/b978-012455900-4/50289-0 · Cited by 1
Study of immunomics and immune regulation in ovarian cancer
Aziz, A. (2013) · Spiral (Imperial College London) · doi:10.25560/23897 · Cited by 1
NanoAPC deliver antigen, IL-2 and co-stimulatory molecules to antigen specific T cells and activate viral specific T cells in chronic infections
Liu, M. (2011) · Brunel University Research Archive (BURA) (Brunel University London) · Cited by 1
Development of a Cancer Vaccine Targeting Tumor Blood Vessels
Huijbers, E. J. M. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Development of CD4+ T cell lines that suppress an antigen-specific immune responsein vivo
de Moraes, L. V., Sun, B., & Rizzo, L. V. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02018.x · Cited by 1
Request for Reprints
Ramanan, S. V. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.20.2509-a · Cited by 1
The Tumor Microenvironment
Coukos, G., & Conejo-Garcia, J. R. (2006) · Humana Press eBooks · doi:10.1385/1-59745-011-1:285 · Cited by 1
Phénotypes et fonctions des lymphocytes T en pathologie tumorale
Badoual, C., Vingert, B., Agueznay, N. E. H., Adotévi, O., Haicheur, N., Molina, T. J., Bruneval, P., Fridman, W. H., & Tartour, É. (2005) · Annales de Pathologie · doi:10.1016/s0242-6498(05)80112-9 · Cited by 1
The Prognostic Significance of Tumor-Infiltrating Lymphocytes
Yu, P., & Fu, Y. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6615-5_19 · Cited by 1
Immuntherapie des Pankreaskarzinoms
Ellermeier, J. (2013) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.16522 · Cited by 1
Vaccine-Primed Lymph Node Cells in the Adoptive Immunotherapy of Cancer: Presence of Host Immune Suppression Induced by Established Cancer
Wei, S., Shreiner, A. B., & Chang, A. E. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_36 · Cited by 1
Defining Multiple Myeloma as a Target for DNA Vaccines
Sahota, S. S., Savelyeva, N., Joseph‐Pietras, D., Zojer, N., & Rice, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5260-7_4
Interleukin-10 in the Control of Tumor Immunity and Autoimmunity.
Wilke, C. M. (2011) · Deep Blue (University of Michigan)
Manipulation of Lymphocyte Homeostasis for Enhancing Antitumor Immunity
Dávila, E., & Celis, E. (2006) · Humana Press eBooks · doi:10.1385/1-59745-011-1:303
Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy
Pardoll, D. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50078-x
Dendritic Cells are Both Targets and Initiators of Peripheral Immune Tolerance to Self
Farkas, A. M. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
NEGATIVE MODULATION OF REGULATORY T CELLS AND PROMOTION OF THE TUMORICIDAL ACTIVITY OF DENDRITIC CELLS IN CANCER: A DOUBLE-EDGED STRATEGY
LaCasse, C. J. (2011) · UA Campus Repository (The University of Arizona)
Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma
Inman, B. A., Frigola, X., Dong, H., Yang, J. C., & Kwon, E. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_21
ON IMMUNOTHERAPY AGAINST PROSTATE CANCER
Lundberg, K. (2010) · Figshare
Tumorvakzinierung beim metastasierten Nierenzellkarzinom
Heine, A., Holderried, T. A. W., & Brossart, P. (2010) · Onkopipeline · doi:10.1007/s15035-010-0176-6

Authors: Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M.
Affiliations: Leiden University Medical Center (NL)
aDepartment of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, Netherlands
The Netherlands Cancer Institute (NL)
University of California, Berkeley (US)
ORCID: Schumacher, Ton N.M.
Wildenberg, Manon E.
Allison, James P.
Offringa, Rienk
Melief, Cornelis J.M.
Venue: The Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2001-09-17
Volume: 194
Issue: 6
Pages: 823-832
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.194.6.823
PMC: PMC2195955
OpenAlex: W2148911309
Cited by: 1,008
References: 44
Citations by year: 2026: 3 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 11 · 2018: 12 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 26 · 2013: 48 · 2012: 41
FWCI: 13.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: cc-by-nc-sa
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4 blockade, CD25+ regulatory T cells, Treg depletion, antitumor immunity, B16 melanoma, CD8+ T cells, tyrosinase-related protein 2, immune regulation, tumor rejection
MeSH terms: Abatacept, Animals, Antibodies, Monoclonal, Antigens, Differentiation, Antigens, Neoplasm, Female, Immunotherapy, Lymphocyte Depletion, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Nude, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Receptors, Interleukin-2, Biomarkers, CD4-Positive T-Lymphocytes, Antigens, CD, Immunoconjugates, Intramolecular Oxidoreductases, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks